Compare companies
Put any US companies we track side by side — SEC-sourced financials, ratios, forensic scores, and our Quality Score. Add up to four. No market price, no paywall.
Bolt Biotherapeutics, Inc.
| Metric | Bolt Biotherapeutics, Inc. BOLTHealthcare |
|---|---|
| Quality Score | 48 / 100 |
| Revenue (latest) | $8M |
| Net income (latest) | −$33M |
| Operating margin | −469.3% |
| Net margin | −433.7% |
| Return on equity | −125.9% |
| Return on assets | −58.8% |
| Return on capital (ROCE) | −74.7% |
| Debt / equity | 1.14× |
| Revenue growth (YoY) | 0.1% |
| Altman Z″ (distress) | -27.30 |
| Accruals / assets | 11.4% |
Latest reported figures from each company's own SEC filings (XBRL) plus our derived scores. Blank where a line item isn't cleanly tagged — never estimated. Descriptive factors, not advice. Open a company for its full multi-year history.